In conclusion, DC-based immunotherapies, particularly vaccination, TLR ligands, and CD40 agonists, have demonstrated the ability to induce DC-specific anti-tumor immune responses associated with improved survival across a range of difficult to treat tumor types, including immune-cold and those resistant to standard immunotherapies. The gene discussed is CD40; the disease is neoplasm.